Compounds > colistin sulfate
Page last updated: 2024-12-06

colistin sulfate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID71457944
CHEMBL ID2218908
MeSH IDM0004768

Synonyms (5)

Synonym
colimycin sulphate
colistin sulphate
CHEMBL2218908
colistins sulphate
belcomycine

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"Using an in vitro pharmacodynamic model, a multidrug-resistant strain of Acinetobacter baumannii was exposed to colistin methanesulfonate alone and in combination with ceftazidime."( Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model.
Hovde, LB; Kroeger, LA; Mitropoulos, IF; Rotschafer, JC; Schafer, J, 2007)		0.34

Bioavailability

ExcerptReferenceRelevance
"An early prediction of solubility in physiological media (PBS, SGF and SIF) is useful to predict qualitatively bioavailability and absorption of lead candidates."( Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
Bharate, SS; Vishwakarma, RA, 2015)		0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (97)

Assay IDTitleYearJournalArticle
AID582436Antibacterial activity against Acinetobacter baumannii ATCC 17978 by broth microdilution test in absence of ferric chloride2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582342Antibacterial activity against Acinetobacter baumannii AB0057 assessed as bacterial population at 1.4 ug/ml2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582213Effect on morphological changes in colistin-resistant Acinetobacter baumannii ATCC 19606 Col10 assessed as change in average root mean squared surface roughness at stationary phase at 0.5 ug/ml after 20 mins by atomic force microscopic analysis2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Atomic force microscopy investigation of the morphology and topography of colistin-heteroresistant Acinetobacter baumannii strains as a function of growth phase and in response to colistin treatment.
AID582085Effect on morphological changes in colistin-susceptible Acinetobacter baumannii ATCC 19606 assessed as change in width of cellular dimension at mid-log phase at 4 ug/ml after 20 mins by atomic force microscopic analysis2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Atomic force microscopy investigation of the morphology and topography of colistin-heteroresistant Acinetobacter baumannii strains as a function of growth phase and in response to colistin treatment.
AID582337Antibacterial activity against Acinetobacter baumannii AB0057 after 1 hr2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582376Antibacterial activity against Acinetobacter baumannii ATCC 17978 assessed as bacterial survival at pH 5.5 after 1 hr2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582086Effect on morphological changes in colistin-susceptible Acinetobacter baumannii ATCC 19606 assessed as change in width of cellular dimension at mid-log phase at 32 ug/ml after 20 mins by atomic force microscopic analysis2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Atomic force microscopy investigation of the morphology and topography of colistin-heteroresistant Acinetobacter baumannii strains as a function of growth phase and in response to colistin treatment.
AID582437Antibacterial activity against Acinetobacter baumannii ATCC 17978 by broth microdilution test in presence of ferric chloride2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582451Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 by broth microdilution test in presence of ferric chloride2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582348Antibacterial activity against Acinetobacter baumannii MAC102 harboring PmrB A227V mutant by broth microdilution test2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID1193493Thermodynamic equilibrium solubility, log S of the compound in PBS at pH 7.4 at RT after 4 hrs by 96 well plate method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID582362Increase of pmrA gene expression in Acinetobacter baumannii MAC201 harboring PmrB T13N, PmrB P233S mutant by RT-PCR analysis relative to 16S rRNA expression2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582091Effect on morphological changes in colistin-susceptible Acinetobacter baumannii ATCC 19606 assessed as change in average root mean squared surface roughness at mid-log phase at 4 ug/ml after 20 mins by atomic force microscopic analysis2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Atomic force microscopy investigation of the morphology and topography of colistin-heteroresistant Acinetobacter baumannii strains as a function of growth phase and in response to colistin treatment.
AID582434Antibacterial activity against Acinetobacter baumannii AB0057 by broth microdilution test in absence of ferric chloride2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582341Antibacterial activity against Acinetobacter baumannii AB0057 assessed as bactericidal half life at 1.4 ug/ml2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582371Antibacterial activity against Acinetobacter baumannii MAC203 harboring PmrB T13N, PmrB P233S, PmrB (411-444) deletion mutant at pH 7.7 by broth microdilution test2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582363Increase of pmrA gene expression in Acinetobacter baumannii MAC203 harboring PmrB T13N, PmrB P233S, PmrB (411-444) deletion mutant by RT-PCR analysis relative to 16S rRNA expression2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582210Effect on morphological changes in colistin-resistant Acinetobacter baumannii ATCC 19606 Col10 assessed as change in average root mean squared surface roughness at mid-log phase at 0.5 ug/ml after 20 mins by atomic force microscopic analysis2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Atomic force microscopy investigation of the morphology and topography of colistin-heteroresistant Acinetobacter baumannii strains as a function of growth phase and in response to colistin treatment.
AID582364Antibacterial activity against Acinetobacter baumannii AB0057 at pH 5.5 by broth microdilution test2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582435Antibacterial activity against Acinetobacter baumannii AB0057 by broth microdilution test in presence of ferric chloride2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582432Antibacterial activity against Acinetobacter baumannii MAC203 harboring PmrB T13N, PmrB P233S, PmrB (411-444) deletion mutant assessed as bacterial survival at pH 5.5 after 1 hr2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582439Antibacterial activity against Acinetobacter baumannii MAC203 harboring PmrB T13N, PmrB P233S, PmrB (411-444) deletion mutant by broth microdilution test in presence of ferric chloride2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582215Effect on morphological changes in colistin-resistant Acinetobacter baumannii ATCC 19606 Col10 assessed as change in average root mean squared surface roughness at stationary at 32 ug/ml after 20 mins by atomic force microscopic analysis2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Atomic force microscopy investigation of the morphology and topography of colistin-heteroresistant Acinetobacter baumannii strains as a function of growth phase and in response to colistin treatment.
AID582365Antibacterial activity against Acinetobacter baumannii AB0057 at pH 7.7 by broth microdilution test2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID1193499Thermodynamic equilibrium solubility, log S of the compound simulated intestinal fluid at pH 6.8 at RT after 24 hrs by shake-flask method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID582351Antibacterial activity against Acinetobacter baumannii ATCC 17978 by Etest2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582360Antibacterial activity against Acinetobacter baumannii AB060 harboring PmrB FS209 frameshift mutant by broth microdilution test2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582450Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 by broth microdilution test in absence of ferric chloride2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582372Antibacterial activity against Acinetobacter baumannii AB060 harboring PmrB FS209 frameshift mutant at pH 5.5 by broth microdilution test2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582206Effect on morphological changes in colistin-susceptible Acinetobacter baumannii ATCC 19606 assessed as change in average root mean squared surface roughness at stationary phase at 32 ug/ml after 20 mins by atomic force microscopic analysis2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Atomic force microscopy investigation of the morphology and topography of colistin-heteroresistant Acinetobacter baumannii strains as a function of growth phase and in response to colistin treatment.
AID582356Antibacterial activity against Acinetobacter baumannii MAC203 harboring PmrB T13N, PmrB P233S, PmrB (411-444) deletion mutant by broth microdilution test2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582440Antibacterial activity against Acinetobacter baumannii MAC201 harboring PmrB T13N, PmrB P233S mutant by broth microdilution test in absence of ferric chloride2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582358Antibacterial activity against Acinetobacter baumannii ACCA152 harboring PmrB P233T mutant by broth microdilution test2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID584099Antibacterial activity against colistin-resistant Acinetobacter baumannii ATCC 19606R exhibiting complete loss of lipopolysaccharide production by broth microdilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production.
AID582347Antibacterial activity against Acinetobacter baumannii MAC102 harboring PmrB A227V mutant by Etest2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582370Antibacterial activity against Acinetobacter baumannii MAC203 harboring PmrB T13N, PmrB P233S, PmrB (411-444) deletion mutant at pH 5.5 by broth microdilution test2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582336Increase of pmrA gene expression in Acinetobacter baumannii MAC101 harboring PmrA P102H, PmrB A262P mutant by RT-PCR analysis relative to 16S rRNA expression2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582369Antibacterial activity against Acinetobacter baumannii MAC103 harboring PmrA P102H, PmrB A262P mutant at pH 7.7 by broth microdilution test2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582090Effect on morphological changes in colistin-susceptible Acinetobacter baumannii ATCC 19606 assessed as change in average root mean squared surface roughness at mid-log phase at 0.5 ug/ml after 20 mins by atomic force microscopic analysis2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Atomic force microscopy investigation of the morphology and topography of colistin-heteroresistant Acinetobacter baumannii strains as a function of growth phase and in response to colistin treatment.
AID582367Antibacterial activity against Acinetobacter baumannii ATCC 17978 at pH 7.7 by broth microdilution test2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID584096Antibacterial activity against colistin-resistant Acinetobacter baumannii ATCC 19606R harboring empty plasmid pWH1266 by broth microdilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production.
AID582338Antibacterial activity against Acinetobacter baumannii AB0057 at up to 4 ug/ml2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582366Antibacterial activity against Acinetobacter baumannii ATCC 17978 at pH 5.5 by broth microdilution test2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582209Effect on morphological changes in colistin-resistant Acinetobacter baumannii ATCC 19606 Col10 assessed as change in diameter of cellular dimension at mid-log phase at 32 ug/ml after 20 mins by atomic force microscopic analysis2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Atomic force microscopy investigation of the morphology and topography of colistin-heteroresistant Acinetobacter baumannii strains as a function of growth phase and in response to colistin treatment.
AID582355Antibacterial activity against Acinetobacter baumannii MAC203 harboring PmrB T13N, PmrB P233S, PmrB (411-444) deletion mutant by Etest2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID1193494Thermodynamic equilibrium solubility, log S of the compound in simulated gastric fluid at pH 1.2 at RT after 4 hrs by 96 well plate method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1193497Thermodynamic equilibrium solubility, log S of the compound PBS at pH 7.4 at RT after 24 hrs by shake-flask method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID582349Antibacterial activity against Acinetobacter baumannii MAC103 harboring PmrA P102H, PmrB A262P mutant by Etest2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582357Antibacterial activity against Acinetobacter baumannii ACCA152 harboring PmrB P233T mutant by Etest2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582444Antibacterial activity against Acinetobacter baumannii ATCC 17978 assessed as bacterial survival after 1 hr in absence of ferric chloride2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582204Effect on morphological changes in colistin-susceptible Acinetobacter baumannii ATCC 19606 assessed as change in average root mean squared surface roughness at stationary phase at 0.5 ug/ml after 20 mins by atomic force microscopic analysis2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Atomic force microscopy investigation of the morphology and topography of colistin-heteroresistant Acinetobacter baumannii strains as a function of growth phase and in response to colistin treatment.
AID582350Antibacterial activity against Acinetobacter baumannii MAC103 harboring PmrA P102H, PmrB A262P mutant by broth microdilution test2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID1193495Thermodynamic equilibrium solubility, log S of the compound in simulated intestinal fluid at pH 6.8 at RT after 4 hrs by 96 well plate method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID582352Antibacterial activity against Acinetobacter baumannii ATCC 17978 by broth microdilution test2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582442Antibacterial activity against Acinetobacter baumannii AB0057 assessed as bacterial survival after 1 hr in absence of ferric chloride2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582088Effect on morphological changes in colistin-susceptible Acinetobacter baumannii ATCC 19606 assessed as change in length of cellular dimension at mid-log phase at 4 ug/ml after 20 mins by atomic force microscopic analysis2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Atomic force microscopy investigation of the morphology and topography of colistin-heteroresistant Acinetobacter baumannii strains as a function of growth phase and in response to colistin treatment.
AID582212Effect on morphological changes in colistin-resistant Acinetobacter baumannii ATCC 19606 Col10 assessed as change in average root mean squared surface roughness at mid-log phase at 32 ug/ml after 20 mins by atomic force microscopic analysis2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Atomic force microscopy investigation of the morphology and topography of colistin-heteroresistant Acinetobacter baumannii strains as a function of growth phase and in response to colistin treatment.
AID584097Antibacterial activity against colistin-resistant Acinetobacter baumannii ATCC 19606R harboring pAL840 plasmid encoding intact lpxA gene by broth microdilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production.
AID1193498Thermodynamic equilibrium solubility, log S of the compound simulated gastric fluid at pH 1.2 at RT after 24 hrs by shake-flask method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID582208Effect on morphological changes in colistin-resistant Acinetobacter baumannii ATCC 19606 Col10 assessed as change in diameter of cellular dimension at mid-log phase at 4 ug/ml after 20 mins by atomic force microscopic analysis2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Atomic force microscopy investigation of the morphology and topography of colistin-heteroresistant Acinetobacter baumannii strains as a function of growth phase and in response to colistin treatment.
AID369576Antibacterial activity against multidrug-resistant Acinetobacter baumannii 06-74 isolate by CLSI microdilution test2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model.
AID582368Antibacterial activity against Acinetobacter baumannii MAC103 harboring PmrA P102H, PmrB A262P mutant at pH 5.5 by broth microdilution test2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582087Effect on morphological changes in colistin-susceptible Acinetobacter baumannii ATCC 19606 assessed as change in length of cellular dimension at mid-log phase at 0.5 ug/ml after 20 mins by atomic force microscopic analysis2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Atomic force microscopy investigation of the morphology and topography of colistin-heteroresistant Acinetobacter baumannii strains as a function of growth phase and in response to colistin treatment.
AID582089Effect on morphological changes in colistin-susceptible Acinetobacter baumannii ATCC 19606 assessed as change in length of cellular dimension at mid-log phase at 32 ug/ml after 20 mins by atomic force microscopic analysis2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Atomic force microscopy investigation of the morphology and topography of colistin-heteroresistant Acinetobacter baumannii strains as a function of growth phase and in response to colistin treatment.
AID582340Antibacterial activity against Acinetobacter baumannii AB0057 assessed as bacterial survival at 1.4 ug/ml after 1 hr2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582449Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 at pH 7.7 by broth microdilution test2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582211Effect on morphological changes in colistin-resistant Acinetobacter baumannii ATCC 19606 Col10 assessed as change in average root mean squared surface roughness at mid-log phase at 4 ug/ml after 20 mins by atomic force microscopic analysis2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Atomic force microscopy investigation of the morphology and topography of colistin-heteroresistant Acinetobacter baumannii strains as a function of growth phase and in response to colistin treatment.
AID582339Antibacterial activity against Acinetobacter baumannii ATCC 17978 at up to 4 ug/ml after 1 hr2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582214Effect on morphological changes in colistin-resistant Acinetobacter baumannii ATCC 19606 Col10 assessed as change in average root mean squared surface roughness at stationary phase at 4 ug/ml after 20 mins by atomic force microscopic analysis2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Atomic force microscopy investigation of the morphology and topography of colistin-heteroresistant Acinetobacter baumannii strains as a function of growth phase and in response to colistin treatment.
AID582445Antibacterial activity against Acinetobacter baumannii ATCC 17978 assessed as bacterial survival after 1 hr in presence of ferric chloride2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582205Effect on morphological changes in colistin-susceptible Acinetobacter baumannii ATCC 19606 assessed as change in average root mean squared surface roughness at stationary phase at 4 ug/ml after 20 mins by atomic force microscopic analysis2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Atomic force microscopy investigation of the morphology and topography of colistin-heteroresistant Acinetobacter baumannii strains as a function of growth phase and in response to colistin treatment.
AID582207Effect on morphological changes in colistin-resistant Acinetobacter baumannii ATCC 19606 Col10 assessed as change in diameter of cellular dimension at mid-log phase at 0.5 ug/ml after 20 mins by atomic force microscopic analysis2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Atomic force microscopy investigation of the morphology and topography of colistin-heteroresistant Acinetobacter baumannii strains as a function of growth phase and in response to colistin treatment.
AID582092Effect on morphological changes in colistin-susceptible Acinetobacter baumannii ATCC 19606 assessed as change in average root mean squared surface roughness at mid-log phase at 32 ug/ml after 20 mins by atomic force microscopic analysis2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Atomic force microscopy investigation of the morphology and topography of colistin-heteroresistant Acinetobacter baumannii strains as a function of growth phase and in response to colistin treatment.
AID582433Antibacterial activity against Acinetobacter baumannii MAC203 harboring PmrB T13N, PmrB P233S, PmrB (411-444) deletion mutant assessed as bacterial survival at pH 7.7 after 1 hr2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582443Antibacterial activity against Acinetobacter baumannii AB0057 assessed as bacterial survival after 1 hr in presence of ferric chloride2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID1193496Thermodynamic equilibrium solubility, log S of the compound in water at RT after 24 hrs by shake-flask method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID582353Antibacterial activity against Acinetobacter baumannii MAC201 harboring PmrB T13N, PmrB P233S mutant by Etest2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582359Antibacterial activity against Acinetobacter baumannii AB060 harboring PmrB FS209 frameshift mutant by Etest2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID584100Antibacterial activity against Acinetobacter baumannii ATCC 19606 by broth microdilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production.
AID582375Antibacterial activity against Acinetobacter baumannii AB0057 assessed as bacterial survival at pH 7.7 after 1 hr2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582354Antibacterial activity against Acinetobacter baumannii MAC201 harboring PmrB T13N, PmrB P233S mutant by broth microdilution test2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582346Antibacterial activity against Acinetobacter baumannii MAC101 harboring PmrA P102H, PmrB A262P mutant by broth microdilution test2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582447Antibacterial activity against Acinetobacter baumannii MAC203 harboring PmrB T13N, PmrB P233S, PmrB (411-444) deletion mutant assessed as bacterial survival after 1 hr in presence of ferric chloride2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582441Antibacterial activity against Acinetobacter baumannii MAC201 harboring PmrB T13N, PmrB P233S mutant by broth microdilution test in presence of ferric chloride2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID1193492Thermodynamic equilibrium solubility, log S of the compound in water at RT after 4 hrs by 96 well plate method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID584098Antibacterial activity against colistin-resistant Acinetobacter baumannii isolate FADDI008R harboring lpxA gene with single base deletion at nucleotide 459 isolated from BALF of ICU patient exhibiting complete loss of lipopolysaccharide production by brot2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production.
AID582361Increase of pmrA gene expression in Acinetobacter baumannii MAC102 harboring PmrB A227V mutant by RT-PCR analysis relative to 16S rRNA expression2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582446Antibacterial activity against Acinetobacter baumannii MAC203 harboring PmrB T13N, PmrB P233S, PmrB (411-444) deletion mutant assessed as bacterial survival after 1 hr in absence of ferric chloride2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582084Effect on morphological changes in colistin-susceptible Acinetobacter baumannii ATCC 19606 assessed as change in width of cellular dimension at mid-log phase at 0.5 ug/ml after 20 mins by atomic force microscopic analysis2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Atomic force microscopy investigation of the morphology and topography of colistin-heteroresistant Acinetobacter baumannii strains as a function of growth phase and in response to colistin treatment.
AID582373Antibacterial activity against Acinetobacter baumannii AB060 harboring PmrB FS209 frameshift mutant at pH 7.7 by broth microdilution test2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582377Antibacterial activity against Acinetobacter baumannii ATCC 17978 assessed as bacterial survival at pH 7.7 after 1 hr2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582345Antibacterial activity against Acinetobacter baumannii MAC101 harboring PmrA P102H, PmrB A262P mutant by Etest2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582438Antibacterial activity against Acinetobacter baumannii MAC203 harboring PmrB T13N, PmrB P233S, PmrB (411-444) deletion mutant by broth microdilution test in absence of ferric chloride2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582374Antibacterial activity against Acinetobacter baumannii AB0057 assessed as bacterial survival at pH 5.5 after 1 hr2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582448Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 at pH 5.5 by broth microdilution test2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582343Antibacterial activity against Acinetobacter baumannii AB0057 by Etest2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
AID582344Antibacterial activity against Acinetobacter baumannii AB0057 by broth microdilution test2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
pyrazinamide
pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.		2.1110monocarboxylic acid amide;
N-acylammonia;
pyrazines		antitubercular agent;
prodrug
acetaminophen
Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.. paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.		2.1110acetamides;
phenols		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
cyclooxygenase 3 inhibitor;
environmental contaminant;
ferroptosis inducer;
geroprotector;
hepatotoxic agent;
human blood serum metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
albendazole
[no description available]		2.1110aryl sulfide;
benzimidazoles;
benzimidazolylcarbamate fungicide;
carbamate ester		anthelminthic drug;
microtubule-destabilising agent;
tubulin modulator
anastrozole
[no description available]		2.1110nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
aspirin
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.		2.1110benzoic acids;
phenyl acetates;
salicylates		anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent
carbamazepine
Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.. carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.		2.1110dibenzoazepine;
ureas		analgesic;
anticonvulsant;
antimanic drug;
drug allergen;
EC 3.5.1.98 (histone deacetylase) inhibitor;
environmental contaminant;
glutamate transporter activator;
mitogen;
non-narcotic analgesic;
sodium channel blocker;
xenobiotic
cetirizine
Cetirizine: A potent second-generation histamine H1 antagonist that is effective in the treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Unlike many traditional antihistamines, it does not cause drowsiness or anticholinergic side effects.. cetirizine : A member of the class of piperazines that is piperazine in which the hydrogens attached to nitrogen are replaced by a (4-chlorophenyl)(phenyl)methyl and a 2-(carboxymethoxy)ethyl group respectively.		2.1110ether;
monocarboxylic acid;
monochlorobenzenes;
piperazines		anti-allergic agent;
environmental contaminant;
H1-receptor antagonist;
xenobiotic
chlorzoxazone
Chlorzoxazone: A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202). chlorzoxazone : A member of the class of 1,3-benzoxazoles that is 1,3-benzoxazol-2-ol in which the hydrogen atom at position 5 is substituted by chlorine. A centrally acting muscle relaxant with sedative properties, it is used for the symptomatic treatment of painful muscle spasm.		2.11101,3-benzoxazoles;
heteroaryl hydroxy compound;
organochlorine compound		muscle relaxant;
sedative
ciprofloxacin
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.		2.4720aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion		antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic
clotrimazole
[no description available]		2.1110conazole antifungal drug;
imidazole antifungal drug;
imidazoles;
monochlorobenzenes		antiinfective agent;
environmental contaminant;
xenobiotic
embelin
embelin: from Embelia fruit (Myrsinaceae). embelin : A member of the class of dihydroxy-1,4-benzoquinones that is 2,5-dihydroxy-1,4-benzoquinone which is substituted by an undecyl group at position 3. Isolated from Lysimachia punctata and Embelia ribes, it exhibits antimicrobial, antineoplastic and inhibitory activity towards hepatitis C protease.		2.1110dihydroxy-1,4-benzoquinonesantimicrobial agent;
antineoplastic agent;
hepatitis C protease inhibitor;
plant metabolite
fluconazole
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.		2.1110conazole antifungal drug;
difluorobenzene;
tertiary alcohol;
triazole antifungal drug		environmental contaminant;
P450 inhibitor;
xenobiotic
ibuprofen
Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine		2.1110monocarboxylic acidantipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
radical scavenger;
xenobiotic
indomethacin
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.		2.1110aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
isoniazid
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).		2.1110carbohydrazideantitubercular agent;
drug allergen
khellin
Khellin: A vasodilator that also has bronchodilatory action. It has been employed in the treatment of angina pectoris, in the treatment of asthma, and in conjunction with ultraviolet light A, has been tried in the treatment of vitiligo. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1024). khellin : A furanochrome in which the basic tricyclic skeleton is substituted at positions 4 and 9 with methoxy groups and at position 7 with a methyl group. A major constituent of the plant Ammi visnaga it is a herbal folk medicine used for various illnesses, its main effect being as a vasodilator.		2.1110furanochromone;
organic heterotricyclic compound;
oxacycle		anti-asthmatic agent;
bronchodilator agent;
cardiovascular drug;
vasodilator agent
loratadine
Loratadine: A second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (HISTAMINE H1 ANTAGONISTS) it lacks central nervous system depressing effects such as drowsiness.. loratadine : A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders.		2.1110benzocycloheptapyridine;
ethyl ester;
N-acylpiperidine;
organochlorine compound;
tertiary carboxamide		anti-allergic agent;
cholinergic antagonist;
geroprotector;
H1-receptor antagonist
nifedipine
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.		2.1110C-nitro compound;
dihydropyridine;
methyl ester		calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent
nimodipine
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.. nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.		2.11102-methoxyethyl ester;
C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
isopropyl ester		antihypertensive agent;
calcium channel blocker;
cardiovascular drug;
vasodilator agent
omeprazole
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.. 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.		2.1110aromatic ether;
benzimidazoles;
pyridines;
sulfoxide
tinidazole
Tinidazole: A nitroimidazole alkylating agent that is used as an antitrichomonal agent against TRICHOMONAS VAGINALIS; ENTAMOEBA HISTOLYTICA; and GIARDIA LAMBLIA infections. It also acts as an antibacterial agent for the treatment of BACTERIAL VAGINOSIS and anaerobic bacterial infections.. tinidazole : 1H-imidazole substituted at C-1 by a (2-ethylsulfonyl)ethyl group, at C-2 by a methyl group and at C-5 by a nitro group. It is used as an antiprotozoal, antibacterial agent.		2.1110imidazolesantiamoebic agent;
antibacterial drug;
antiparasitic agent;
antiprotozoal drug
colchicine
(S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.		2.1110alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen
ampicillin
Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.		2.0310beta-lactam antibiotic;
penicillin allergen;
penicillin		antibacterial drug
glycyrrhetinic acid
[no description available]		2.1110cyclic terpene ketone;
hydroxy monocarboxylic acid;
pentacyclic triterpenoid		immunomodulator;
plant metabolite
acetylcysteine
N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.		2.1110acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary
Berberine chloride (TN)
[no description available]		2.1110organic molecular entity
streptomycin
[no description available]		2.1110antibiotic antifungal drug;
antibiotic fungicide;
streptomycins		antibacterial drug;
antifungal agrochemical;
antimicrobial agent;
antimicrobial drug;
bacterial metabolite;
protein synthesis inhibitor
amikacin
Amikacin: A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics.. amikacin : An amino cyclitol glycoside that is kanamycin A acylated at the N-1 position by a 4-amino-2-hydroxybutyryl group.		2.0310alpha-D-glucoside;
amino cyclitol glycoside;
aminoglycoside;
carboxamide		antibacterial drug;
antimicrobial agent;
nephrotoxin
simvastatin
Simvastatin: A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.. simvastatin : A member of the class of hexahydronaphthalenes that is lovastatin in which the 2-methylbutyrate ester moiety has been replaced by a 2,2-dimethylbutyrate ester group. It is used as a cholesterol-lowering and anti-cardiovascular disease drug.		2.1110delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
statin (semi-synthetic)		EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
ferroptosis inducer;
geroprotector;
prodrug
valsartan
Valsartan: A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION.. valsartan : A monocarboxylic acid amide consisting of L-valine in which the amino hydrogens have been replaced by a pentanoyl and a [2'-(1H-tetrazol-5-yl)biphenyl]-4-yl]methyl group. It exhibits antihypertensive activity.		2.1110biphenylyltetrazole;
monocarboxylic acid amide;
monocarboxylic acid		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
terfenadine
[no description available]		2.1110diarylmethane
telmisartan
Telmisartan: A biphenyl compound and benzimidazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION.. telmisartan : A member of the class of benzimidazoles used widely in the treatment of hypertension.		2.1110benzimidazoles;
biphenyls;
carboxybiphenyl		angiotensin receptor antagonist;
antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
environmental contaminant;
xenobiotic
aceclofenac
[no description available]		2.1110amino acid;
carboxylic ester;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
clarithromycin
Clarithromycin: A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit PROTEIN SYNTHESIS in BACTERIA by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation.. clarithromycin : The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.		2.1110macrolide antibioticantibacterial drug;
environmental contaminant;
protein synthesis inhibitor;
xenobiotic
imipenem, anhydrous
Imipenem: Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.. imipenem : A broad-spectrum, intravenous beta-lactam antibiotic of the carbapenem subgroup.		2.0310beta-lactam antibiotic allergen;
carbapenems;
zwitterion		antibacterial drug
docetaxel
[no description available]		2.1110hydrate;
secondary alpha-hydroxy ketone		antineoplastic agent
levofloxacin
Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.		2.03109-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid;
fluoroquinolone antibiotic;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
meropenem
Meropenem: A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients.. meropenem : A carbapenemcarboxylic acid in which the azetidine and pyrroline rings carry 1-hydroxymethyl and in which the azetidine and pyrroline rings carry 1-hydroxymethyl and 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio substituents respectively.		2.0310alpha,beta-unsaturated monocarboxylic acid;
carbapenemcarboxylic acid;
organic sulfide;
pyrrolidinecarboxamide		antibacterial agent;
antibacterial drug;
drug allergen
fluticasone propionate
fluticasone propionate : A trifluorinated corticosteroid that consists of 6alpha,9-difluoro-11beta,17alpha-dihydroxy-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-16-methyl-3-oxoandrosta-1,4-diene bearing a propionyl substituent at position 17; has anti-inflammatory, anti-asthmatic and anti-allergic activity.		2.111011beta-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
corticosteroid;
fluorinated steroid;
propanoate ester;
steroid ester;
thioester		adrenergic agent;
anti-allergic agent;
anti-asthmatic drug;
anti-inflammatory drug;
bronchodilator agent;
dermatologic drug
zithromax
Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.		2.0510macrolide antibioticantibacterial drug;
environmental contaminant;
xenobiotic
piperine
piperine : A N-acylpiperidine that is piperidine substituted by a (1E,3E)-1-(1,3-benzodioxol-5-yl)-5-oxopenta-1,3-dien-5-yl group at the nitrogen atom. It is an alkaloid isolated from the plant Piper nigrum.		2.1110benzodioxoles;
N-acylpiperidine;
piperidine alkaloid;
tertiary carboxamide		food component;
human blood serum metabolite;
NF-kappaB inhibitor;
plant metabolite
tamoxifen
[no description available]		2.1110stilbenoid;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
diclofenac sodium
Diclofenac Sodium: The sodium form of DICLOFENAC. It is used for its analgesic and anti-inflammatory properties.. diclofenac sodium : The sodium salt of diclofenac.		2.1110organic sodium salt
amphotericin b
Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.		2.1110antibiotic antifungal drug;
macrolide antibiotic;
polyene antibiotic		antiamoebic agent;
antiprotozoal drug;
bacterial metabolite
pulmicort
Budesonide: A glucocorticoid used in the management of ASTHMA, the treatment of various skin disorders, and allergic RHINITIS.. budesonide : A glucocorticoid steroid having a highly oxygenated pregna-1,4-diene structure. It is used mainly in the treatment of asthma and non-infectious rhinitis and for treatment and prevention of nasal polyposis.		2.111011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
cyclic acetal;
glucocorticoid;
primary alpha-hydroxy ketone		anti-inflammatory drug;
bronchodilator agent;
drug allergen
gardenia yellow
gardenia yellow: extract of gardenia fruit; RN given refers to cpd with unknown MF. crocin-1 : A diester that is crocetin in which both of the carboxy groups have been converted to their gentiobiosyl esters. It is one of the water-soluble yellow-red pigments of saffron and is used as a spice for flavouring and colouring food. Note that in India, the term 'Crocin' is also used by GlaxoSmithKline as a brand-name for paracetamol.		2.1110diester;
disaccharide derivative;
diterpenoid		antioxidant;
food colouring;
histological dye;
plant metabolite
mangiferin
shamimin: isolated from the leaves of Bombax ceiba; structure in first source		2.1110C-glycosyl compound;
xanthones		anti-inflammatory agent;
antioxidant;
hypoglycemic agent;
plant metabolite
terbinafine hydrochloride
terbinafine hydrochloride : A hydrochloride obtained by reaction of terbinafine with one molar equivalent of hydrogen chloride.		2.1110allylamine antifungal drug;
hydrochloride		EC 1.14.13.132 (squalene monooxygenase) inhibitor;
P450 inhibitor
cefepime
Cefepime: A fourth-generation cephalosporin antibacterial agent that is used in the treatment of infections, including those of the abdomen, urinary tract, respiratory tract, and skin. It is effective against PSEUDOMONAS AERUGINOSA and may also be used in the empiric treatment of FEBRILE NEUTROPENIA.. cefepime : A cephalosporin bearing (1-methylpyrrolidinium-1-yl)methyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.		2.0510cephalosporin;
oxime O-ether		antibacterial drug
ceftazidime
[no description available]		2.0310cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen;
EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
aztreonam
[no description available]		2.0310beta-lactam antibiotic allergen;
monobactam		antibacterial drug;
drug allergen;
EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
nitrofurantoin
Nitrofurantoin: A urinary anti-infective agent effective against most gram-positive and gram-negative organisms. Although sulfonamides and antibiotics are usually the agents of choice for urinary tract infections, nitrofurantoin is widely used for prophylaxis and long-term suppression.. nitrofurantoin : An imidazolidine-2,4-dione that is hydantoin substituted at position 1 by a [(5-nitro-2-furyl)methylene]amino group. An antibiotic that damages bacterial DNA.		2.0310imidazolidine-2,4-dione;
nitrofuran antibiotic;
organonitrogen heterocyclic antibiotic;
organooxygen heterocyclic antibiotic		antibacterial drug;
antiinfective agent;
hepatotoxic agent
roxithromycin
(E)-roxithromycin : A major geometrical isomer of roxithromycin.		2.1110roxithromycinenvironmental contaminant;
xenobiotic
gentamicin sulfate
[no description available]		2.0310
cambogin
isogarcinol: has immunosuppresant activity; isolated from Garcinia mangostana; structure in first source		2.1110
ascorbic acid
Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants.. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms.		2.1110ascorbic acid;
vitamin C		coenzyme;
cofactor;
flour treatment agent;
food antioxidant;
food colour retention agent;
geroprotector;
plant metabolite;
skin lightening agent
mobic
Meloxicam: A benzothiazine and thiazole derivative that acts as a NSAID and cyclooxygenase-2 (COX-2) inhibitor. It is used in the treatment of RHEUMATOID ARTHRITIS; OSTEOARTHRITIS; and ANKYLOSING SPONDYLITIS.. meloxicam : A benzothiazine that is piroxicam in which the pyridin-2-yl group is replaced by a 5-methyl-1,3-thiazol-2-yl group. A non-steroidal anti-inflammatory drug and selective inhibitor of COX-2, it is used particularly for the management of rheumatoid arthritis.		2.11101,3-thiazoles;
benzothiazine;
monocarboxylic acid amide		analgesic;
antirheumatic drug;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		2.1110cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
aplysinopsin
aplysinopsin: antineoplastic tryptophan deriv from Verongia spengetii (marine sponge); structure		2.1110
ConditionIndicatedRelationship StrengthStudiesTrials